3SBio (DE:83B)
FRANKFURT:83B
83B Stock Chart & Stats
€2.69
>-€0.01(-0.71%)
At close: 4:00 PM EST
€2.69
>-€0.01(-0.71%)
Day’s Range― - ―
52-Week Range€1.63 - €3.88
Previous CloseN/A
Volume0.00
Average Volume (3M)105.00
Market Cap
€4.58B
Enterprise Value€24.92B
Total Cash (Recent Filing)€19.73B
Total Debt (Recent Filing)€2.62B
Price to Earnings (P/E)4.1
Beta0.36
Next Earnings
Aug 26, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.41
Shares Outstanding2,538,084,500
10 Day Avg. Volume205
30 Day Avg. Volume105
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.97
Price to Sales (P/S)3.03
P/FCF Ratio5.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.87Price Target Upside43.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.12
Revenue Forecast (FY)€1.13B
Bulls Say, Bears Say
Bulls Say
Step-change ProfitabilityThe 2025 margin and revenue step-change indicates durable operational leverage from higher-priced biologics and scaled commercialization. If sustained, these margins support strong cash flow, fund R&D, and enable competitive reinvestment in manufacturing and distribution over the medium term.
Strong Cash GenerationFree cash flow near net income in 2025 reflects high earnings quality and substantial cash conversion at scale. Robust cash generation improves financial flexibility to invest in new launches, reduce leverage, support working capital and pay dividends or pursue strategic partnerships long term.
Conservative LeverageA markedly lower debt-to-equity ratio reduces interest burden and balance sheet risk, enabling resilience through cycles. Stronger equity and asset base after 2025 gives capacity for capex, manufacturing scale-up, or M&A without materially stressing liquidity over the coming quarters.
Bears Say
Sustainability Risk Of 2025 SpikeThe exceptional 2025 performance follows several years of uneven results, suggesting part of the gain could be cyclical, one-off, or tied to specific product/timing effects. Persistent reliance on similar drivers is required to make current earnings durable over the next 2–6 months and beyond.
Variable Cash ConversionPrior years' weaker cash conversion points to working-capital and timing volatility that can reappear. Irregular cash conversion increases forecasting risk for capex, R&D and payouts, and can force short-term financing or constrain strategic investments if trends revert.
China Reimbursement & Procurement ExposureRevenue is concentrated in the Chinese hospital market where centralized procurement and reimbursement policy can compress prices and alter product mix. Structural regulatory or reimbursement shifts could reduce revenues or margins materially over a multi-month horizon.
3SBio News
83B FAQ
What was 3SBio’s price range in the past 12 months?
3SBio lowest stock price was €1.63 and its highest was €3.88 in the past 12 months.
What is 3SBio’s market cap?
3SBio’s market cap is €4.58B.
When is 3SBio’s upcoming earnings report date?
3SBio’s upcoming earnings report date is Aug 26, 2026 which is in 67 days.
How were 3SBio’s earnings last quarter?
3SBio released its earnings results on Mar 30, 2026. The company reported €0.369 earnings per share for the quarter, missing the consensus estimate of €0.459 by -€0.09.
Is 3SBio overvalued?
According to Wall Street analysts 3SBio’s price is currently Undervalued.
Does 3SBio pay dividends?
3SBio does not currently pay dividends.
What is 3SBio’s EPS estimate?
3SBio’s EPS estimate is 0.08.
How many shares outstanding does 3SBio have?
3SBio has 2,538,084,500 shares outstanding.
What happened to 3SBio’s price movement after its last earnings report?
3SBio reported an EPS of €0.369 in its last earnings report, missing expectations of €0.459. Following the earnings report the stock price went up 3.906%.
Which hedge fund is a major shareholder of 3SBio?
Currently, no hedge funds are holding shares in DE:83B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
3SBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
456.34%
12-Months-Change
Fundamentals
Return on Equity
38.96%
Trailing 12-Months
Asset Growth
56.38%
Trailing 12-Months
Company Description
3SBio
Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
83B Stock 12 Month Forecast
Average Price Target
€3.87
▲(43.68% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---